AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

European Patent Office Grants 3rd Charpentier/Doudna Patent Covering Uses of CRISPR/Cas9 in Human and Animals Cells

April 3, 2019

DUBLIN--(BUSINESS WIRE)--Apr 3, 2019--ERS Genomics Limited announced today that the European Patent Office (EPO) has issued a new patent to Dr. Emmanuelle Charpentier, The Regents of the University of California and University of Vienna. EPO Patent No. 3,401,400 claims methods and compositions of using CRISPR/Cas9 to modify DNA and regulate gene activity in eukaryotic cells, including kits to carry out such work. ERS Genomics provides broad access to these and other foundational CRISPR/Cas9 patents co-owned by Dr. Emmanuelle Charpentier.

Eric Rhodes, CEO of ERS Genomics, said:The most common use for CRISPR/Cas9 is in eukaryotic cells, including human and animal cells.We are pleased to have another comprehensive patent covering methods, compositions and kits for such uses which adds to our portfolio of patents which have issued in over 40 countries worldwide.”

For additional information please visit www.ersgenomics.com

ENDS

View source version on businesswire.com:https://www.businesswire.com/news/home/20190403005359/en/

CONTACT: Media contact:

Katie Odgaard

Zyme Communications

Tel: +44(0)7787 502 947

Email:katie.odgaard@zymecommunications.com

KEYWORD: EUROPE IRELAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS

SOURCE: ERS Genomics

Copyright Business Wire 2019.

PUB: 04/03/2019 05:41 AM/DISC: 04/03/2019 05:41 AM

http://www.businesswire.com/news/home/20190403005359/en